The estimated Net Worth of Burke W Whitman is at least $1.17 Million dollars as of 1 November 2021. Mr. Whitman owns over 1,500 units of Amicus Therapeutics Inc stock worth over $733,474 and over the last 6 years he sold FOLD stock worth over $0. In addition, he makes $433,247 as Independent Director at Amicus Therapeutics Inc.
Burke has made over 36 trades of the Amicus Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 1,500 units of FOLD stock worth $15,735 on 1 November 2021.
The largest trade he's ever made was buying 4,945 units of Amicus Therapeutics Inc stock on 23 August 2019 worth over $49,796. On average, Burke trades about 859 units every 20 days since 2018. As of 1 November 2021 he still owns at least 65,082 units of Amicus Therapeutics Inc stock.
You can see the complete history of Mr. Whitman stock trades at the bottom of the page.
Burke W. Whitman serves as Independent Director of the Company. Since 2019, he has also served as a member of the Board of Directors of Omega Healthcare Investors (NYSE: OHI) (Audit Committee); member of the Reserve Forces Policy Board (Advisor to the Secretary of Defense); and member of the Board of Trustees of The Lovett School (Atlanta). In business from 1988 to 2008, he served as Chief Executive Officer and initially Chief Operating Officer of Health Management Associates (NYSE: HMA) 2005-08; Chief Financial Officer of Triad Hospitals (NYSE: TRI) 1998-2005; President of Deerfield Healthcare (private) 1994-98; Vice President of Finance of Almost Family (Nasdaq: AFAM) 1992-94; and Investment Banker with Morgan Stanley (NYSE: MS) 1988-92. Concurrently in national service 1985-2019, he served as a reserve officer of the United States Marine Corps, including active duty 1985 to 1988 and 2009 to 2018, where he led five combat deployments, was the Commanding General of 4th Marine Division and Marine Forces Reserve, served with the Secretary of Defense, and retired as a Major General and the Corps’ senior reservist. Mr. Whitman previously served on the Board Directors of the Toys for Tots Foundation (Investment Chair), Board of Directors of the Federation of American Hospitals (Audit Chair), Board of Visitors of Marine Corps University, and Founders Group of the National Museum of the Marine Corps. Mr. Whitman earned a B.A. from Dartmouth College, a Master of Strategic Studies degree from the Army War College, and an M.B.A. from Harvard Business School.
As the Independent Director of Amicus Therapeutics Inc, the total compensation of Burke Whitman at Amicus Therapeutics Inc is $433,247. There are 10 executives at Amicus Therapeutics Inc getting paid more, with John Crowley having the highest compensation of $9,852,660.
Burke Whitman is 64, he's been the Independent Director of Amicus Therapeutics Inc since 2019. There are 1 older and 17 younger executives at Amicus Therapeutics Inc. The oldest executive at Amicus Therapeutics Inc is Robert Essner, 72, who is the Independent Director.
Burke's mailing address filed with the SEC is 303 International Cir #200, Cockeysville, MD 21030, USA.
Over the last 17 years, insiders at Amicus Therapeutics Inc have traded over $306,740,337 worth of Amicus Therapeutics Inc stock and bought 23,821,602 units worth $176,323,212 . The most active insiders traders include Advisors Llcperceptive Life..., Peter J Barris und Plc Gsk. On average, Amicus Therapeutics Inc executives and independent directors trade stock every 10 days with the average trade being worth of $830,419. The most recent stock trade was executed by Bradley L Campbell on 3 September 2024, trading 7,500 units of FOLD stock currently worth $64,575.
amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g
Amicus Therapeutics Inc executives and other stock owners filed with the SEC include: